Upgrade to SI Premium - Free Trial

Deciphera Pharmaceuticals (DCPH) Misses Q4 EPS by 13c

March 9, 2020 4:04 PM

Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 EPS of ($1.31), $0.13 worse than the analyst estimate of ($1.18).

“2019 was a year of outstanding execution for Deciphera,” said Steve Hoerter, President and Chief Executive Officer. “In 2020, our top priority is preparing for the potential approval and launch of ripretinib now that the NDA has been accepted by the FDA for Priority Review. Patients with GIST are in need of a new treatment option, and we believe ripretinib has the potential to transform the treatment of this disease.”

Mr. Hoerter continued, “Our broad development program for ripretinib is on track, and we look forward to the completion of enrollment in INTRIGUE, our pivotal Phase 3 study of ripretinib in second-line GIST, in the second half of this year. Beyond ripretinib, we remain focused on the balance of our wholly-owned, clinical-stage pipeline, with updated clinical data for both DCC-3014 and rebastinib, as well as an IND submission for DCC-3116, expected later this year.”

For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.

Categories

Corporate News Earnings Management Comments

Next Articles